Get the Stockscreener App
1.73
0.00%
0.00
Skye Bioscience Inc stock is traded at $1.73, with a volume of 465.14K.
It is up +0.00% in the last 24 hours and down -59.29% over the past month.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
See More
Previous Close:
$1.73
Open:
$1.67
24h Volume:
465.14K
Relative Volume:
0.63
Market Cap:
$50.13M
Revenue:
-
Net Income/Loss:
$-42.37M
P/E Ratio:
-1.6189
EPS:
-1.0686
Net Cash Flow:
$-34.94M
1W Performance:
-8.95%
1M Performance:
-59.29%
6M Performance:
+22.70%
1Y Performance:
-59.67%
1-Day Range:
$1.57
$1.70
1-Week Range:
$1.57
$2.0999
52-Week Range:
$1.14
$5.96
Skye Bioscience Inc Stock (SKYE) Company Profile
Name
Skye Bioscience Inc
Sector
Industry
Phone
(858) 410-0266
Address
11250 EL CAMINO REAL, SUITE 100, SAN DIEGO
Compare SKYE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SKYE
Skye Bioscience Inc.
|
3.10 | 12.89M | 0 | 0 | 0 | 0.00 |
|
MOBBW
Mobilicom Limited Warrants
|
4.00 | 5.31B | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.00 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
2.60 | 113.25M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.2109 | 445.05M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
DAVEW
Dave Inc
|
1.00 | 0 | 0 | 0 | 0 | 0.00 |
Skye Bioscience Inc Stock (SKYE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-06-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-06-25 | Downgrade | Craig Hallum | Buy → Hold |
| Aug-15-25 | Initiated | Evercore ISI | Outperform |
| Feb-28-25 | Initiated | William Blair | Outperform |
| Sep-30-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-10-24 | Initiated | JMP Securities | Mkt Outperform |
| Jul-09-24 | Initiated | Craig Hallum | Buy |
| May-23-24 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-12-24 | Initiated | Oppenheimer | Outperform |
View All
Skye Bioscience Inc Stock (SKYE) Latest News
Is Skye Bioscience Inc. stock a defensive play in 20252025 Market Trends & Accurate Buy Signal Alerts - newser.com
Is it too late to sell Skye Bioscience Inc.July 2025 Fed Impact & AI Driven Price Forecasts - newser.com
How Skye Bioscience Inc. stock performs in weak economyWeekly Stock Recap & Safe Investment Capital Preservation Plans - newser.com
Is Skye Bioscience Inc a good long term investmentDividend Stability Analysis & Superior Trading Ideas - earlytimes.in
Predicting Skye Bioscience Inc. trend using moving averagesQuarterly Portfolio Summary & Technical Confirmation Trade Alerts - newser.com
Will Skye Bioscience Inc. stock benefit from upcoming earnings reportsEarnings Overview Summary & Momentum Based Trading Signals - newser.com
FY2026 EPS Forecast for Skye Bioscience Raised by Analyst - MarketBeat
Will Skye Bioscience Inc. bounce back from current supportTrend Reversal & Free Safe Capital Growth Stock Tips - newser.com
Using Ichimoku Cloud for Skye Bioscience Inc. technicalsInsider Buying & Short-Term High Return Ideas - newser.com
Skye Bioscience Inc. stock daily chart insightsJuly 2025 Weekly Recap & Fast Momentum Entry Tips - newser.com
Analyzing Skye Bioscience Inc. with risk reward ratio chartsMarket Growth Report & Weekly High Potential Stock Alerts - newser.com
Why retail investors favor Skye Bioscience Inc. stock2025 Sector Review & Daily Chart Pattern Signal Reports - newser.com
Weiss Ratings Reaffirms "Sell (D-)" Rating for Skye Bioscience (NASDAQ:SKYE) - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Skye Bioscience, Inc.SKYE - PR Newswire
What analysts say about Skye Bioscience Inc 09R stockEx-Dividend Date Alerts & Free Discover Dynamic Stocks - earlytimes.in
Skye plummets 60% on mid-stage data for nimacimab for weight loss - MSN
Why Did Skye Bioscience Stock Plummet A Whopping 60% Today? - MSN
Skye Bioscience (SKYE) Receives a Buy from Oppenheimer - The Globe and Mail
SKYE Stock Plunges 60% as Obesity Candidate Misses Key Phase II Goal - Yahoo Finance
Why Skye Bioscience (SKYE) Is Down 51.0% After Releasing Phase 2a Nimacimab Trial Results and What's Next - Yahoo Finance
Skye Bioscience's Investigational Drug Disappoints As Monotherapy For Weight Loss - Sahm
Skye's obesity drug misses mid-stage trial main goal, shares tank - ET Pharma
Oppenheimer Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating, Cuts Target Price to $10 - 富途牛牛
Skye Bioscience Reports Topline CBeyond™ Phase 2a Data from - GlobeNewswire
Citizens lowers Skye Bioscience stock price target to $4 from $16, maintains Market Outperform rating - Investing.com
Oppenheimer lowers Skye Bioscience stock price target to $10 on mixed trial data - Investing.com
Craig Hallum Downgrades Skye Bioscience (NASDAQ:SKYE) to Hold - MarketBeat
Nasdaq Jumps Over 150 Points; Skye Bioscience Shares Plunge - Benzinga
Spruce Biosciences Stock Is Soaring Today: Here's Why - Benzinga
Skye Bioscience (NASDAQ:SKYE) Lowered to "Neutral" Rating by Cantor Fitzgerald - MarketBeat
Skye Bioscience says nimacimab did not meet primary endpoint in CBeyond study - TipRanks
US Stocks Mixed; Dow Falls 100 Points - Benzinga
Skye Bioscience downgraded to Neutral from Overweight at Cantor Fitzgerald - TipRanks
Skye shares crash as obesity drug falls short in key study - BioPharma Dive
Skye Biosciences (SKYE) Shares Plunge After Trial Setback - GuruFocus
Is It Too Late to Buy SKYE? - timothysykes.com
Skye Bioscience Reveals Phase 2a Study Results - TipRanks
Why Is Skye Bioscience Stock Down 60% Today? - TipRanks
Skye Says CBeyond Phase 2a Study Of Nimacimab Monotherapy Did Not Meet Primary Endpoint - Nasdaq
Skye Bioscience (SKYE) Reveals Phase 2a Study Results for Nimaci - GuruFocus
Skye Bioscience stock plummets after failed weight loss drug trial - Investing.com
Skye Bioscience's obesity drug fails to meet main goal of mid-stage study - MarketScreener
Skye Bioscience reports early trial data for Cbeyond combo and solo use of Nimacimab - MarketScreener
Applying Elliott Wave Theory to Skye Bioscience Inc.Weekly Trend Summary & Low Risk High Win Rate Stock Picks - newser.com
Skye’s CB1-blocking obesity drug fails in mid-stage study - statnews.com
Skye Bioscience Reports Topline CBeyond™ Phase 2a Data from Nimacimab Monotherapy and Combination Clinical Trial - Yahoo Finance
Will Skye Bioscience Inc. (09R) stock recover faster than industry2025 Top Decliners & Safe Swing Trade Setups - newser.com
Using data models to predict Skye Bioscience Inc. stock movementShare Buyback & Real-Time Volume Spike Alerts - newser.com
Best data tools to analyze Skye Bioscience Inc. stockTrade Exit Summary & Weekly High Potential Stock Alerts - newser.com
Is Skye Bioscience Inc. (09R) stock a momentum leaderQuarterly Portfolio Report & Smart Investment Allocation Insights - newser.com
Smart tools for monitoring Skye Bioscience Inc.’s price actionTrade Volume Summary & Reliable Price Breakout Alerts - newser.com
Skye Bioscience Inc Stock (SKYE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Skye Bioscience Inc Stock (SKYE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Schwab Andrew J. | Director |
Aug 21 '25 |
Sale |
3.57 |
60,956 |
217,613 |
63,963 |
| 5AM Partners VII, LLC | 10% Owner |
Aug 22 '25 |
Sale |
3.42 |
170,449 |
582,936 |
57,493 |
| 5AM Partners VII, LLC | 10% Owner |
Aug 21 '25 |
Sale |
3.57 |
60,956 |
217,613 |
63,963 |
| Diep Tuan Tu | Chief Development Officer |
Nov 18 '24 |
Sale |
4.99 |
19,489 |
97,250 |
82,259 |
| Diep Tuan Tu | Chief Development Officer |
Nov 15 '24 |
Sale |
5.55 |
85 |
472 |
101,748 |
| ARSENAULT KAITLYN | Chief Financial Officer |
Nov 18 '24 |
Sale |
4.99 |
43,206 |
215,598 |
166,342 |
| ARSENAULT KAITLYN | Chief Financial Officer |
Nov 15 '24 |
Sale |
5.55 |
190 |
1,054 |
209,548 |
| DHILLON PUNIT | Chief Executive Officer |
Nov 18 '24 |
Sale |
4.99 |
82,546 |
411,905 |
329,823 |
| DHILLON PUNIT | Chief Executive Officer |
Nov 15 '24 |
Sale |
5.55 |
364 |
2,020 |
412,369 |
| Grayson Paul A. | Director |
Nov 18 '24 |
Sale |
4.99 |
86,244 |
430,358 |
259,701 |
0.21%
2.95%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):